MarginsXMarginsX
Home › Markets › Health Care › KYNB

Kyntra Bio Inc. (KYNB)

KYNB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.20
-8.31% on the day
Market cap
$13.0M
Nano cap
Revenue · 2025
$6.4M
-78.3% on 2024
Net income · 2025
$183.5M
2848.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/921299/000119312526108346/0001193125-26-108346-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKYNB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0000921299
SEC industry codePharmaceutical Preparations
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$6.4M
Net income$183.5M
Operating income-$45.9M
Net margin2848.6%
Operating margin-712.7%
Revenue growth-78.3%
Cash$47.9M
Total assets$119.6M
P/E (computed)0.1×
P/S (computed)2.0×

Warning signs

Cash runway
16.0 months
$50.6M cash at June 30, 2026
Share count, 1 year
+0.1%
2025-07-31 to 2026-07-31 · +3.1% over 3 years
Going-concern doubt
No
10-Q filed August 13, 2026
Insider net buying, 12 months
$54K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-13
Cash and burn$50.6M cash; operating cash flow -$9.5M a quarter.Report 2026-06-30
Shares outstanding4,049,124 (2026-07-31); 4,043,899 a year earlier; 98,210,168 three years earlier. 3y figure adjusted for split (1-for-25 overall).Cover page 2026-07-31
Reverse splits, 3 years1; latest 1-for-25 on 2025-06-17Source 2025-06-17
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-10-06
AuditorPricewaterhouseCoopers LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $54K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
-$1.5M$12.0M-$4.0M$50.6MNo debt tags$4.6M10-Q 2026-08-13
Q1 2026
2026-03-31
$3.7M-$15.2M-$13.9M$37.0MNo debt tags$7.4M10-Q 2026-05-12
Q4 2025
2025-12-31
$1.3M-$14.2M-$18.3M$47.9MNo debt tags$6.4M10-K 2026-03-16
Q3 2025
2025-09-30
$1.1M$200.6M-$1.8M$118.0MNo debt tags$8.3M10-Q 2025-11-10
Q2 2025
2025-06-30
$1.3M-$7.6M$12.7M$23.4MNo debt tags$7.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$2.7M$4.6M$2.7M$33.6MNo debt tags$7.0M10-Q 2026-05-12
Q4 2024
2024-12-31
$3.1M$18.0M-$30.5M$50.5MNo debt tags$29.6M10-K 2026-03-16
Q3 2024
2024-09-30
$123K-$17.1M-$8.4M$131.0MNo debt tags-$47.3M10-Q 2025-11-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-02-24
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.8%
1 month-41.4%
3 months-51.1%
Year to date-60.8%
1 year-62.1%
From 52-week high-65.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CMMBChemomab Therapeutics Ltd. American Depositary Share$1.62+5.88%$13.0M
NEUPNeuphoria Therapeutics Inc.$2.48-2.75%$13.4M
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$1.44-10.56%$12.2M
MRKRMarker Therapeutics Inc.$0.8286-4.76%$13.8M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier